Sarclisa Combinations Show Promise in Multiple Myeloma Treatment

Sanofi has reported new findings on Sarclisa-based treatments for multiple myeloma, presented at the American Society of Hematology (ASH) Annual Meeting. The data highlights significant benefits in patients with newly diagnosed multiple myeloma (NDMM). The IMROZ phase 3 study observed higher minimal residual disease (MRD) negativity in transplant-ineligible patients using Sarclisa-VRd compared to VRd alone. This improvement could be linked to enhanced progression-free survival (PFS).

In a separate GMMG-HD7 phase 3 study, Sarclisa-RVd showed a considerable PFS benefit in transplant-eligible patients, with higher MRD negativity observed. This study underlines Sarclisa’s potential in initial treatment settings. Both studies confirm Sarclisa’s safety and align with previous safety profiles. The findings support Sarclisa as a robust therapy option in NDMM management, suggesting sustained advancements in treatment outcomes.